{"id":37240,"date":"2026-01-27T17:30:27","date_gmt":"2026-01-27T16:30:27","guid":{"rendered":"https:\/\/mabdesign.fr\/?p=37240"},"modified":"2026-01-27T17:43:53","modified_gmt":"2026-01-27T16:43:53","slug":"charles-river-announce-proposed-acquisition-of-pathoquest","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/","title":{"rendered":"Charles River announce proposed acquisition of PathoQuest"},"content":{"rendered":"\n<p>Charles River has announced its proposed acquisition of PathoQuest. Since 2016, Charles River and PathoQuest have partnered to provide clients with access to PathoQuest\u2019s NGS solutions, and the proposed acquisition is expected to strengthen Charles River\u2019s existing Biologics Testing capabilities by adding rapid, in vitro GMP and non-GMP testing solutions.<\/p>\n\n\n\n<p>PathoQuest\u2019s innovative NGS approach supports Charles River\u2019s Alternative Methods Advancement Project (AMAP) initiative by utilizing new approach methodologies (NAMs) to replace animal use in viral safety workflows, while also accelerating clients\u2019 quality-control testing timelines and the overall biologics development process.<br><br><a href=\"https:\/\/ir.criver.com\/news-releases\/news-release-details\/charles-river-laboratories-provides-business-updates\">To know more<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Charles River has announced its proposed acquisition of PathoQuest. Since 2016, Charles River and PathoQuest have partnered to provide clients with access to PathoQuest\u2019s NGS solutions, and the proposed acquisition is expected to strengthen Charles River\u2019s existing Biologics Testing capabilities by adding rapid, in vitro GMP and non-GMP testing solutions.<\/p>\n","protected":false},"author":6,"featured_media":37241,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32,18],"tags":[],"class_list":["post-37240","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-our-members","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Charles River announce proposed acquisition of PathoQuest - MabDesign<\/title>\n<meta name=\"description\" content=\"Charles River has announced its proposed acquisition of PathoQuest. Since 2016, Charles River and PathoQuest have partnered to provide clients with access to PathoQuest\u2019s NGS solutions, and the proposed acquisition is expected to strengthen Charles River\u2019s existing Biologics Testing capabilities by adding rapid, in vitro GMP and non-GMP testing solutions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Charles River announce proposed acquisition of PathoQuest - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Charles River has announced its proposed acquisition of PathoQuest. Since 2016, Charles River and PathoQuest have partnered to provide clients with access to PathoQuest\u2019s NGS solutions, and the proposed acquisition is expected to strengthen Charles River\u2019s existing Biologics Testing capabilities by adding rapid, in vitro GMP and non-GMP testing solutions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-27T16:30:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-27T16:43:53+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/charles-river-logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1601\" \/>\n\t<meta property=\"og:image:height\" content=\"343\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Maissa Pote\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maissa Pote\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/\"},\"author\":{\"name\":\"Maissa Pote\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029\"},\"headline\":\"Charles River announce proposed acquisition of PathoQuest\",\"datePublished\":\"2026-01-27T16:30:27+00:00\",\"dateModified\":\"2026-01-27T16:43:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/\"},\"wordCount\":103,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/charles-river-logo.png\",\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/\",\"name\":\"Charles River announce proposed acquisition of PathoQuest - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/charles-river-logo.png\",\"datePublished\":\"2026-01-27T16:30:27+00:00\",\"dateModified\":\"2026-01-27T16:43:53+00:00\",\"description\":\"Charles River has announced its proposed acquisition of PathoQuest. Since 2016, Charles River and PathoQuest have partnered to provide clients with access to PathoQuest\u2019s NGS solutions, and the proposed acquisition is expected to strengthen Charles River\u2019s existing Biologics Testing capabilities by adding rapid, in vitro GMP and non-GMP testing solutions.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/charles-river-logo.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/charles-river-logo.png\",\"width\":1601,\"height\":343},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Charles River announce proposed acquisition of PathoQuest\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029\",\"name\":\"Maissa Pote\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g\",\"caption\":\"Maissa Pote\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/communication\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Charles River announce proposed acquisition of PathoQuest - MabDesign","description":"Charles River has announced its proposed acquisition of PathoQuest. Since 2016, Charles River and PathoQuest have partnered to provide clients with access to PathoQuest\u2019s NGS solutions, and the proposed acquisition is expected to strengthen Charles River\u2019s existing Biologics Testing capabilities by adding rapid, in vitro GMP and non-GMP testing solutions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/","og_locale":"en_US","og_type":"article","og_title":"Charles River announce proposed acquisition of PathoQuest - MabDesign","og_description":"Charles River has announced its proposed acquisition of PathoQuest. Since 2016, Charles River and PathoQuest have partnered to provide clients with access to PathoQuest\u2019s NGS solutions, and the proposed acquisition is expected to strengthen Charles River\u2019s existing Biologics Testing capabilities by adding rapid, in vitro GMP and non-GMP testing solutions.","og_url":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/","og_site_name":"MabDesign","article_published_time":"2026-01-27T16:30:27+00:00","article_modified_time":"2026-01-27T16:43:53+00:00","og_image":[{"width":1601,"height":343,"url":"http:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/charles-river-logo.png","type":"image\/png"}],"author":"Maissa Pote","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Maissa Pote","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/"},"author":{"name":"Maissa Pote","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029"},"headline":"Charles River announce proposed acquisition of PathoQuest","datePublished":"2026-01-27T16:30:27+00:00","dateModified":"2026-01-27T16:43:53+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/"},"wordCount":103,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/charles-river-logo.png","articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/","url":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/","name":"Charles River announce proposed acquisition of PathoQuest - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/charles-river-logo.png","datePublished":"2026-01-27T16:30:27+00:00","dateModified":"2026-01-27T16:43:53+00:00","description":"Charles River has announced its proposed acquisition of PathoQuest. Since 2016, Charles River and PathoQuest have partnered to provide clients with access to PathoQuest\u2019s NGS solutions, and the proposed acquisition is expected to strengthen Charles River\u2019s existing Biologics Testing capabilities by adding rapid, in vitro GMP and non-GMP testing solutions.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/charles-river-logo.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/charles-river-logo.png","width":1601,"height":343},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/charles-river-announce-proposed-acquisition-of-pathoquest\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Charles River announce proposed acquisition of PathoQuest"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029","name":"Maissa Pote","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g","caption":"Maissa Pote"},"url":"https:\/\/mabdesign.fr\/en\/author\/communication\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/37240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=37240"}],"version-history":[{"count":2,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/37240\/revisions"}],"predecessor-version":[{"id":37248,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/37240\/revisions\/37248"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/37241"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=37240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=37240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=37240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}